Trial Profile
A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema (HAE)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Dyax
- 05 Jun 2014 Status changed from not stated to withdrawn prior to recruitment.
- 05 Jun 2014 New trial record